Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "AI"

8753 News Found

Richter’s FYLREVY to transform menopause care in Europe?
News | February 04, 2026

Richter’s FYLREVY to transform menopause care in Europe?

The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses


ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
Clinical Trials | February 04, 2026

ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer

The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy


Siemens Healthineers launches €10 million R&D hub in Swords, Ireland
R&D | February 04, 2026

Siemens Healthineers launches €10 million R&D hub in Swords, Ireland

The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders


Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
News | February 04, 2026

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway


Cirena launches to revolutionize long RNA production for CRISPR & gene editing
News | February 04, 2026

Cirena launches to revolutionize long RNA production for CRISPR & gene editing

As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects


Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
R&D | February 04, 2026

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project


China nod to Darolutamide for metastatic hormone-sensitive prostate cancer
News | February 04, 2026

China nod to Darolutamide for metastatic hormone-sensitive prostate cancer

The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT


SPARC announces receipt of priority review voucher associated with Sezaby approval
News | February 04, 2026

SPARC announces receipt of priority review voucher associated with Sezaby approval

A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases